Group,ID,Age,Sex,PD duration (years),MoCA,LID duration (years),BDI,MDS-UPDRS-III,MDS-UPDRS-III,AIMS,Anti-PD medications
Unnamed: 0_level_1,Unnamed: 1_level_1,Unnamed: 2_level_1,Unnamed: 3_level_1,Unnamed: 4_level_1,Unnamed: 5_level_1,Unnamed: 6_level_1,Unnamed: 7_level_1,OFF,ON,Unnamed: 10_level_1,Unnamed: 11_level_1
LID,PD02,76.0,M,6.0,22.0,2.5,12.0,31.0,19.0,2.0,LD. Amantadine
,PD03,66.0,M,11.0,23.0,1.25,6.0,20.0,10.0,1.0,LD. DA
,PD05,73.0,M,18.0,21.0,6.0,9.0,52.0,43.0,3.0,LD. Amantadine
,PD09,55.0,M,5.0,24.0,1.5,6.0,37.0,30.0,2.0,LD.
,PD10,65.0,F,14.0,29.0,8.0,10.0,37.0,21.0,3.0,LD. Amantadine
Non-LID,PD01,55.0,M,5.0,30.0,,0.0,19.0,9.0,0.0,LD. Amantadine
,PD04,71.0,M,7.0,29.0,,4.0,31.0,30.0,0.0,LD. DA.MOA-B.
,PD06,64.0,M,4.0,23.0,,5.0,53.0,14.0,0.0,LD.
,PD07,68.0,M,8.0,27.0,,8.0,22.0,16.0,0.0,LD.
,PD08,77.0,F,10.0,29.0,,4.0,24.0,23.0,0.0,LD.MOA-B
P-value,,1.0,,0.22,0.07,,0.13,0.32,0.49,0.004,
